Komboglyze · DIN 02389169 · 2.5 mg & 500 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2026-06-12 — choose a marketed DIN from the same-category list.Discontinued June 12, 2026 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-06-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-06-12 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Komboglyze · DIN 02389169
Manufacturer: AstraZeneca; listing date 2014-11-27
Health Canada: Cancelled post market since 2026-06-12 · brand KOMBOGLYZE · ATC A10BD10 METFORMIN AND SAXAGLIPTIN · form Tablet · route Oral · ingredients SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) 2.5 MG, METFORMIN HYDROCHLORIDE 500 MG · company Astrazeneca canada inc · schedule Prescription
Komboglyze: Formulary list price $1.47 per unit (the source does not state the unit; exact figure $1.4743). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02389169)
Source record
DIN 02389169: Komboglyze
Raw flags: insOH=Y, sec3=Y
Item: 682002052; group id 755; item number 1852; lccId None; manufacturer id AZC
Source form: Tab; strength: 2.5mg & 500mg
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $1.4743; ministry $1.4743
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02389169
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87467
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since June 12, 2026 — choose a marketed DIN from the same-category list.